Bio-Rad Laboratories Inc - Class A risk profile
55 Elevated one input has moved against it
Measured 21 October 2026 from BIO's filed statements. Recomputed nightly.
55 (Elevated), driven by Competitive position at 78, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 31 | Normal | Stable | One-year price volatility — 36.5% |
| Operating pressure | 62 | Stretched | Worsening | Operating-margin drift — -15.4 percentage points |
| Cash conversion | 36 | Normal | Worsening | Cash conversion — 0.70x |
| Leverage and coverage | 37 | Normal | Worsening | Net debt to EBITDA — 3.16x |
| Competitive position | 78 | Stretched | Stable | Operating-margin gap against peers — -10.0 percentage points |
| Concentration | 39 | Normal | Stable | Geographic concentration — 3,169 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Bio-Rad Laboratories Inc - Class A